Mereo BioPharma Group plc
MREO Nasdaq
SEC CIK 1719714
Follow Mereo BioPharma
Weekly email: filings, results
Net income
−£34.2M
EPS, diluted
−£0.06
−400% vs prior year
Operating cash flow
−£38.8M
−641% vs prior year
Operating income
−£43.6M
−108.1% vs prior year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY22 | −£34.2M |
| FY21 | - |
| FY20 | −£163.6M |
| FY19 | −£34.8M |
| FY18 | −£32M |
| FY17 | −£38.8M |
| FY16 | −£28.4M |
| FY15 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY22 | −£38.8M |
| FY21 | −£5.8M |
| FY20 | −£28.4M |
| FY19 | −£46M |
| FY18 | −£23.2M |
| FY17 | −£32.2M |
| FY16 | −£29.7M |
| FY15 | - |